Article
Integrative proteomic and gene expression analysis identify potential biomarkers for adjuvant trastuzumab resistance: analysis from the Fin-her phase III randomized trial.
Oncotarget - 6 Oct 2015
Sonnenblick Amir, Brohée Sylvain, Fumagalli Debora, Rothé Françoise, Vincent Delphine, Ignatiadis Michael, Desmedt Christine, Salgado Roberto, Sirtaine Nicolas, Loi Sherene, Neven Patrick, Loibl Sibylle, Denkert Carsten, Joensuu Heikki, Piccart Martine, Sotiriou Christos
Abstract excerpt
Trastuzumab is a remarkably effective therapy for patients with human epidermal growth factor receptor 2 (HER2)--positive breast cancer (BC). However, not all women with high levels of HER2 benefit from trastuzumab. By integrating mRNA and protein expression data from Reverse-Phase Protein Array Analysis (RPPA) in HER2-positive BC, we developed gene expression metagenes that reflect pathway activation levels....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.